α9-Containing Nicotinic Receptors in Cancer

Susanna Pucci1,2, Michele Zoli3, Francesco Clementi1,4 and Cecilia Gotti1,2*

1Institute of Neuroscience, National Research Council (CNR), Milan, Italy, 2NeuroMi Milan Center for Neuroscience, University of Milano Bicocca, Milan, Italy, 3Department of Biomedical, Metabolic and Neural Sciences, Center for Neuroscience and Neurotechnology (CINN), University of Modena and Reggio Emilia, Modena, Italy, 4Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy

Neuronal nicotinic acetylcholine receptors containing the α9 or the α9 and α10 subunits are expressed in various extra-neuronal tissues. Moreover, most cancer cells and tissues highly express α9-containing receptors, and a number of studies have shown that they are powerful regulators of responses that stimulate cancer processes such as proliferation, inhibition of apoptosis, and metastasis. It has also emerged that their modulation is a promising target for drug development. The aim of this review is to summarize recent data showing the involvement of these receptors in controlling the downstream signaling cascades involved in the promotion of cancer.

Keywords: nicotinic acetylcholine receptor (nAChR), cancer, lung, breast, glioblastoma, melanoma

INTRODUCTION

There is ample evidence that the risk of developing various types of cancer is greater among smokers than non-smokers (Grando, 2014), although the role of smoking in the etiology of some cancers remains controversial (Li et al., 2016; Shao et al., 2016). Tobacco smoke contains at least 4,000 compounds (nicotine and a number of carcinogenic compounds such as tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, and aldehydes) that are capable of inducing the DNA damaging response that initiates tumorigenesis and enhances the spread of metastases. The risk and severity of cancer depend on the duration of exposure and the amount of tobacco smoking (Schane et al., 2010).

Nicotine is the most addictive component of tobacco smoke and, although it is unable to initiate tumorigenesis in humans and rodents, it promotes tumor growth and metastasis by inducing cell-cycle progression, migration, epithelial-to-mesenchymal transition, invasion, angiogenesis, and the evasion of apoptosis in a variety of systems (Schaal and Chellappan, 2014; Mucchietto et al., 2016), and ultimately causes multiple cancers to develop resistance to chemotherapeutic drugs (Grando, 2014; Afrashteh Nour et al., 2021). Emerging evidence suggests that there is a pathogenic link between nicotine and an increased susceptibility of cells to malignancies, but the underlying mechanisms are still ill-defined. The primary mechanism underlying the way in which nicotine acts as a tumor promoter is by binding and activating nicotinic acetylcholine receptors (AChRs; Mucchietto et al., 2016), which induce the secretion of the growth factors and cytokines that alter the physiology of various organ systems and can activate a number of intracellular mitogenic signaling pathways to promote cell growth, angiogenesis, and other tissue responses. These receptors represent a highly heterogeneous class of ligand-gated ion channels that are enriched in skeletal muscle (where they transduce nerve-to-muscle communication) and in the central and peripheral nervous systems, where they mediate synaptic transmission (Hurst et al., 2013; Zoli et al., 2015).
Neuronal nicotinic acetylcholine receptors (nAChRs) are a family of subtypes that are mainly heteromeric combinations of nine α (α2-α6) and three β (β2-β4) subunits, or homomeric receptors consisting of α subunits (α7 or α9); these last subunits can also form the heteromeric α7β2 and α9α10 subtypes (Zoli et al., 2015). nAChRs are activated by endogenous ligands such as ACh and choline, and exogenous compounds such as nicotine. The α-bungarotoxin (α-Bgtx) antagonist binds and blocks only some of the nAChR subtypes, which are therefore divided into two main classes: the α-Bgtx-sensitive subtypes, which may be homomeric or heteromeric and consist of the α7, α7β2, α9, and α9α10 subtypes, and the α-Bgtx-insensitive receptors, which are always heteromeric combinations of α (α2-α6) and β (β2-β4) subunits (Gotti et al., 2006; Albuquerque et al., 2009).

Recent studies have clearly shown that nAChRs and their physiological agonist, ACh, are widely expressed in non-neuronal mammalian cells (Grando, 2014; Zoli et al., 2018; Chen et al., 2019) from which ACh is released into the extracellular space in an autocrine, paracrine or juxtacrine manner, and that the cholinergic/nicotinic system plays important roles in various aspects of cell biology and homeostasis (Wessler and Kirkpatrick, 2008; Friedman et al., 2019). nAChRs and their endogenous ligands are also expressed by cancer cells and tissues.

Structure, Pharmacology, and Localization of α9 nAChRs

The various combinations of nAChR subunits lead to the formation of a heterogeneous family of pentameric receptor subtypes that have different structural, functional, and pharmacological properties. In heteromeric nAChRs consisting of α and β subunits, the ACh binding site (also known as the orthosteric site) lies at the interface of the extra-cellular domains of adjacent subunits and consists of a principal component of one α subunit, and a complementary component of the adjacent β structural subunit.

The α9α10 subtype is a heteromeric receptor that only consists of α subunits (α9 and α10), and it has been proposed that α10 may act as a structural subunit, in much the same way as a β subunit of heteromeric nAChRs providing only complementary components to the agonist binding site (Elgoyhen and Katz, 2012). However, recent studies have shown that α9 and α10 subunits equally contribute to the principal component of the α9α10 nAChR binding site, whereas the contribution of α9 and α10 to the complementary component is non-equivalent (Boffi et al., 2017). Experiments on the X-ray crystal structures of the extracellular domain of the monomeric state of the human neuronal α9 subunit and its complexes with a α-Bgtx, methyllycaconitine (MLA; Zouridakis et al., 2014) or the α-conotoxin RgIA (Zouridakis et al., 2019) have shown that, despite the absence of a complementary subunit and transmembrane domain, the α9 extracellular domain has a native folding and can bind MLA, α-Bgtx or α-conotoxin RgIA through its principal component.

The α9α10 subtype may have two different stoichiometries, (α9)2(α10)3 (Plazas et al., 2005) and (α9)3(α10)2 (Indurthi et al., 2014), which have varying sensitivities to ACh and the Vc1.1 α-conotoxin. In addition to the computationally established α9α10 binding site common to both stoichiometries, the (α9)2(α10)3 stoichiometry has an additional, binding site at the α9/α9 interface of low sensitivity for the α-conotoxin Vc1.1 (Indurthi et al., 2014).

On the basis of their sequence similarity to nAChRs, the α9 and α10 subunits were initially classified as neuronal, but the homomeric α9 and the heteromeric α9α10 receptors are not functionally present in the brain (Morley et al., 2018). The α9α10 subtype is only endogenously expressed in cochlear and vestibular hair cells in the inner ear, and in extra-neuronal tissues. Studies of α9 (Vetter et al., 1999) and α10 knockout (KO) mice (Vetter et al., 2007) have demonstrated the physiological role of this subtype in the medial olivocochlear pathway, in which the targeted disruption of the α9 (Vetter et al., 1999) or α10 subunits (Vetter et al., 2007) abolishes ACh-mediated synaptic currents in both inner and outer hair cells. More recently, Morley et al. (2017) have used constitutive α9 and/or α10 KO mice to show that only the doubly constitutive mice showed abnormal efferent innervation of cochlear hair cells. Moreover, a very recent study (Wang et al., 2021) has demonstrated that, in the developing auditory system, α9 and α10-containing receptors are involved in the spontaneous activity generated in the cochlea that propagates to the CNS to promote circuit formation.

α9-containing receptors are also expressed at the splanchnic nerve–chromaffin cell synapse, where they are involved in the excitatory neurotransmission. These receptors are up-regulated in cold-stressed rats where they become a major determinant of ACh-induced current (Colomer et al., 2010).

α9 subunit is also expressed by the cells of the immune system (Lustig et al., 2001; Becker et al., 2015) but unlike in neurons and cochlear hair cells, where α9-containing receptors function as ligand-gated ion channels, in immune cells α9 ligand-evoked ion currents have not been observed (Richter et al., 2016).

The functional properties of α9α10 nAChRs vary widely across species (Marcovich et al., 2020). Xenopus oocytes expression of the mammalian α9 subunit forms functional channels, whereas the rat or human α10 subunit only forms functional channels when it is co-expressed with an α9 subunit. The oocytes co-injection of α9 and α10 subunits leads to a subtype that has the same ACh EC50 as the α9 subtype but greater functional expression (Elgoyhen et al., 1994, 2001).

A number of the pharmacological characteristics of α9 and α9α10 nAChRs are particularly interesting: they are activated by ACh but not by the classical agonist nicotine that blocks ACh-gated currents, and the α9α10 nAChR has a mixed nicotinic and muscarinic profile as it is blocked by the nicotinic antagonists d-tubocurarine and α-Bgtx as well as by the muscarinic antagonist atropine (Elgoyhen et al., 1994, 2001; Sgard et al., 2002).

nAChR-Associated Proteins

All nAChRs are integral membrane proteins that share the same basic topology, and neurotransmitter receptors coupled to an ion-conducting pore. A plethora of proteins and metabolites acting at multiple steps in nAChR biogenesis have recently been discovered (Crespi et al., 2018; Matta et al., 2021): some of
these proteins are endoplasmic reticulum-resident chaperone proteins that are necessary for the proper folding and assembly of some nAChR subtypes, whereas others are auxiliary (accessory) subunits that stably associate with receptors and control channel function.

When expressed in transfected cell lines, the α9α10 subtype is not functional. Genome-wide screening has shown that choline acetyltransferase (ChAT), the biosynthetic enzyme for ACh, and the protein TMIE (Gu et al., 2020) are factors enabling the function of α9α10 nAChRs. Functional studies have demonstrated that the surface expression and assembly of α9α10 nAChRs require the ligand binding of an agonist (ACh) or antagonist (αBgtx), and that mutating the α9α10 ACh binding site abolishes receptor surface expression. They have also shown that the presence of TMIE protein, a deafness gene product, is important for the correct functioning of α9α10 nAChRs: TMIE acts as an auxiliary subunit and, by associating with the α9α10 receptors on the cell surface, promotes their function (Gu et al., 2020).

The proteins that stably associate with nAChRs comprise the L6Y prototoxin family, a family of small modulatory proteins that can interact with numerous targets. These proteins have a three-dimensional structure that is similar to that found in snake venom neurotoxins (Miwa, 2021). Some of them are secreted as water-soluble proteins, and others are bound to cell membranes by a glycosylphosphatidylinositol (GPI) anchor. Lynx1, the first member of the L6Y family to be identified, can form a stable complex and regulate the responses of α4β2 and α7 nAChRs. Lynx1 is expressed in normal and neoplastic lung tissue, but its level is lower in lung cancers than in adjacent normal lung tissue (Fu et al., 2015). The recombinant water-soluble variant of Lynx1 inhibits the growth of adenocarcinoma A549 cells by causing cell cycle arrest via the modulation of α7 nAChRs and the activation of various intra-cellular signaling cascades (Bychkov et al., 2019). Although α9α10 nAChRs have not been detected among the targets of Lynx1, it has been shown that a recently synthesized circularized Lynx1-derived peptide binds to the ligand binding domain of α9 nAChRs and inhibits the rat α9α10 subtype expressed in Xenopus oocytes (Kryukova et al., 2019).

**Ionotropic and Metabotropic nAChR Signaling**

The ionotropic mechanism of inter-cellular signaling mediated by nAChRs has been studied in neurons (Albuquerque et al., 2009; Corringer et al., 2012), and is due to the opening the ionic channel that is an integral part of the receptor and generating cation fluxes that lead to membrane depolarization. This depolarization opens voltage-gated Ca²⁺ channels (VGCCs), and leads to a further Ca²⁺ influx that may induce Ca²⁺-induced Ca²⁺ release (CICR) from the endoplasmic reticulum by activating ryanodine receptors (RyRs; King et al., 2015; Kabbani and Nichols, 2018). The nAChR subtypes with the greatest Ca²⁺ permeability are the homomeric α7 and α9, and the heteromeric α9α10 nAChRs (Fucile et al., 2003, 2006).

In non-excitatory cells, the increase in the concentration of free intracellular Ca²⁺ induced by activation of nAChRs mainly derives from ionic influx through the receptors since VGCCs are poorly expressed.

In astrocytes, whose membrane resting potential is critically lower than that measured in neurons, ionic influx through ligand-gated channels may be largely responsible for the increased intracellular Ca²⁺ levels that modulates Ca²⁺-gated channels locally, and activates various Ca²⁺-dependent signaling mechanisms (Mcneill et al., 2021).

However, over the last decade, it has been shown that α7-, α4-, β2-, and β4-containing nAChRs also have a metabotropic mechanism underlying the neuronal response to nicotinic agonists (Nordman and Kabbani, 2014; King et al., 2015). The metabotropic pathway increases intracellular [Ca²⁺] via Gαq protein coupled with nAChR signal transduction mediated by phospholipase C (PLC) and inositol-trisphosphate (IP₃) receptor-activated Ca²⁺ release from the endoplasmic reticulum (King et al., 2015; Kabbani and Nichols, 2018).

There are new lines of evidence that, in neurons, agonist stimulation of presynaptic α7 nAChRs mediates Ca²⁺ signaling via both ionotropic Ca²⁺ influx through the open-channel state and non-conventional metabotropic channel signaling. Agonist binding to α7 determines sufficient Na⁺ influx-induced depolarization to activate VGCCs and Ca²⁺ influx and lead to RyR-mediated CICR from the endoplasmic reticulum. In addition, the transition of α7 nAChRs to a high-affinity ligand-bound desensitized state supports a metabotropic response marked by G protein activation of PLC, IP₃ production, and IP₃-induced Ca²⁺ release (Papke and Lindstrom, 2020; Borroni and Barrantes, 2021).

Kabbani’s group (King et al., 2015; King and Kabbani, 2016; Kabbani and Nichols, 2018) has shown that the α7 subunit binds Gα and Gβγ proteins through the intracellular M3-M4 loop, and enables a downstream Ca²⁺ signaling response that can persist longer than the expected time course of channel activation and leads to the activation of downstream second messenger pathways such as RhoA GTPase and cytoskeletal changes during neurite growth.

In many non-neuronal cell types, metabotropic signaling after ligand binding is a property of α7 receptors and it is present in immune cells where cholinergic signaling plays an important role in regulating cytokine release even though no ACh-dependent currents have been recorded, and despite the fact that α7 receptors are on the plasma membrane (Fujii et al., 2017; Treinin et al., 2017).

It has also been shown that α9 subunit-containing nAChRs have metabotropic functions. Homomeric α9 nAChRs or heteromeric α9α10 nAChRs heterologously expressed in Xenopus oocytes do not generate ion currents when stimulated with phosphocholine, but do so when stimulated by choline, a metabolite of ACh (Richter et al., 2016) that also acts as an agonist of the α7 nAChR.

Various metabotropic functions of α7 and α9 nAChRs have been described in monocytes, in which choline derivatives (choline, phosphocholine, and ACh) inhibit ATP-mediated IL1β release by blocking purinergic P2X7 receptors (Hecker et al., 2015). The effect of phosphocholine on IL-1β release takes place via activation of the α9α10 metabotropic pathway. ACh
and phosphocholine both inhibit IL-1β release in monocytes, but only the former evokes ion currents through the receptor. Pre-incubation with phosphocholine reduces ACh-evoked ion flux, thus suggesting that phosphocholine acts as a silent agonist that converts α7 or α9 receptors to a long-lived desensitized state that elicits signal transduction independently of ion channel opening (Richter et al., 2016; Papke and Lindstrom, 2020).

In brief, depending on the type of cell and the nAChR subtypes expressed, the binding of ACh or nicotine can induce conformational changes in nAChRs and/or their associated proteins that can activate various intracellular signaling pathways and regulate gene expression.

Methods Used to Study α9-Containing Receptors

A number of approaches have been used to detect nAChRs in many extra-neuronal tissues. Reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-PCR, and in situ hybridization have all been used to show that they are expressed at variable levels in normal and malignant cells, but interpreting the data obtained is not easy because there is not always a correlation between the levels of mRNA and those of the expressed subunit.

The first evidence of α9 nAChR expression came from rat cochlear hair cells, in which α9 nAChRs are involved in auditory functions (Elgoyhen et al., 1994), but many more locations and biological functions of α9 nAChR have since been identified, including keratinocyte adhesion (Nguyen et al., 2000; Chernyavsky et al., 2007), breast epithelial cancer formation (Lee et al., 2010), endocrine activities (Colomer et al., 2010), immune responses (Hecker et al., 2015), inflammation (Liu et al., 2017, 2019), chronic pain (Romero et al., 2017; Hone et al., 2018; Zheng et al., 2021), the homeostasis of osteocytes, and the regulation of bone mass (Baumann et al., 2019).

Supplementary Table 1 summarizes the studies in which the presence of α9- and α9α10-containing receptors has been shown in cancer cells and tissues.

The most convincing identification of α9 nAChRs in such tissues has been obtained by the use of subtype-specific antagonists (Li et al., 2021) that block many cancer-promoting processes and/or by comparing their effects on the wildtype (WT) nAChR subunit and KO mice. It is important to note that the antagonists αBgtx and MLA not only act on α9 nAChRs but also bind with high affinity to α7 nAChRs (Elgoyhen et al., 1994; Verbitsky et al., 2000). Consequently, if they are used to study the in vivo or in vitro effects of nicotine or ACh on native α9 nAChRs, it needs to be remembered that α7 nAChRs may also be involved. In order to differentiate or analyze the effects mediated only by α9 nAChRs, the further use of α9-selective antagonists such as α-conotoxin Vc1.1 (Indurthi et al., 2014), α-O-conotoxin GeXIVA (Luo et al., 2015), RgLA4 (Romero et al., 2017), and PeIA (Mcintosh et al., 2005; Yu et al., 2018) is crucial. Dimeric constructs of the toxins PeIA, Vc1.1, and RgIA* ([AR13]RgIA) have recently been designed, and all three constructs are more potent than their monomeric counterparts in relation to human α9α10 nAChRs (Liang et al., 2020; see Table 1).

Another successful approach to studying the in vitro and in vivo roles of α9- and α10-containing receptors is to over-express or silence them by RNA interference, a very powerful technique that has given important information concerning the involvement of these receptors in physiological and pathological conditions (Lee et al., 2010).

Extensive work has very recently been done to identify human cancer proteins interacting with membrane proteins and determine their downstream regulated pathways using a systematically integrated method. As α9 is an integral membrane protein, Lin et al. (2019) have tried to identify new α9 nAChR interacting and downstream proteins by means of multiple RNA-seq and microarray data relating to different cancers. Using CHRNA9, they identified 18 new representative candidates that were subsequently verified by means of immunoprecipitation and Western blotting. They also found associated proteins that are important for regulated pathways, such as proteins involved in the cell cycle, adherens junctions, and ErbB signaling. These were related to cell growth and communication in more than six cancer types, thus indicating that α9 plays a role in the formation, progression, and metastatic spread of various tumors (Lin et al., 2019).

As recent exhaustive reviews (Schuller, 2009; Grando, 2014; Schaal and Chellappan, 2014) have already considered the mechanisms by means of which nAChRs are involved in cancer signaling pathways, this review will concentrate on the latest published data concerning the role of α9/α9α10 (α9*) receptors in the physiology and pathology of lung, breast, glioblastoma, and melanoma cancers.

α9-Containing Receptors in Lung Cancer

Lung cancer is the most frequent and lethal cancer in the world, accounting for 1.79 million deaths in 2020 (Ferlay et al., 2021) and, although a subset of patients develop lung cancer without a history of smoking, approximately 70% of all cases of non-small cell lung cancer (NSCLC) and 90% of all cases of small cell lung cancer (SCLC) are caused by smoking (Samet et al., 2009; Pesch et al., 2012; Improgo et al., 2013).

A very recent study (Zhang et al., 2020) has shown that nicotine treatment of human lung epithelial cells can create a pro-tumorigenic environment favoring cell transformation or tumorigenesis in lung epithelium by perturbing intracellular redox status and altering p53 function. Together with a study by Tang et al. (2019) showing that mice exposed to nicotine delivered by means of electronic cigarette smoke develop lung adenocarcinoma, this suggests the need for caution when using nicotine replacement therapies and e-cigarettes.

Lung cells express the mRNA of multiple nAChR subunits whose levels are frequently altered in primary NSCLC and SCLC, and their cell lines. It has been found that the levels of α3, α5, β4, and α9 subunit mRNAs are significantly increased in SCLC (Improgo et al., 2010, 2013), and that the levels of α7, α9, and α10 subunit mRNA are also increased in a number of cell lines derived from SCLC and NSCLC tumors (Improgo et al., 2010).

Various studies have shown that the nAChRs present in lung epithelial and endothelial cells play a direct role in lung cancer. In particular, nAChRs are expressed in airway epithelium cells...
that synthesize, store, and secrete the physiological ligand ACh, which acts as an autocrine and paracrine growth factor (Spindel, 2016; Friedman et al., 2019). When lung cancer arises from the airway epithelium, cell growth is stimulated by ACh or nicotine, and this may provide endogenous mitogenic signaling without any further activation.

Inhibiting cholinergic signaling causes apoptosis in bronchioalveolar carcinoma cells (Lau et al., 2013), and nicotine protects lung cancer cells against apoptosis induced by chemotherapy (Liang et al., 2020), oxidative stress, and ionising radiation (Friedman et al., 2019).

Case control studies of NSCLC patients (340) and matching controls (435) have shown that an increased risk of developing lung cancer is associated with two single nucleotide polymorphisms (SNPs) in the CHRNA9 gene: rs56159866 and CHRNA9 rs73229797 allele on the 

| Table 1 | Alkaloid and peptidic antagonists targeting α9-containing receptors. |
|----------------|-----------------|-----------------|
| **Antagonists** | **Target subtypes** | **References** |
| Methyllycaconitine | α6, α7, α9, α9-α10 | Davies et al. (1999), Verbitsky et al. (2000), Elgoyhen et al. (2001), Zoli et al. (2002), and Fucile et al. (2006) |
| α-Bungarotoxin | α7, α9, α9-α10 | Couturier et al. (1990), Elgoyhen et al. (1994), and Elgoyhen et al. (2001) |
| α-conotoxin PeIA | α9-α10 | McIntosh et al. (2005) and Yu et al. (2018) |
| α-conotoxin RgIA | α9-α10 | Ellison et al. (2006) |
| α-conotoxin Vc1.1 | α9-α10 | Indurthi et al. (2014) |
| α-O-conotoxin GeXIVA | α9-α10 | Luo et al. (2015) |
| α-conotoxin RglM | α9-α10 | Romero et al. (2017) |
| Dimeric PeIA, Vc1.1 and RglA# ([ΔR13]RgIA) | α9-α10 | Liang et al. (2020) |

In 2020, it was estimated that breast cancer accounted for about 2.26 million new cases and 682, 000 deaths, thus making it the most frequently diagnosed cancer worldwide, (Ferlay et al., 2021). It is also the second leading cause of cancer-related deaths among women, mostly of which are due to recurrences and metastases (Ferlay et al., 2021).

**α9-Containing Receptors in Breast Cancer**

Studies of A549 adenocarcinoma cells have shown that treatment with a nicotine concentration that is similar to the levels measured in sera of smokers (100 nM) promotes their proliferation (Mucchietto et al., 2018), and this proliferation is blocked by the action of MLA and αBgtx on α7 and α9 receptors, and by subtype-specific α9 (RgIA4) and α7 toxins (AR). The concentration of nicotine increasing cell proliferation was much less than that required to activate α9 or α7 receptors in functional experiments. This suggests that nicotine induced the non-ionic signaling events that regulate the phosphorylation states of the target proteins mediating some of the effects of nicotine on A549 cells (Schaal and Chellappan, 2014). In the same cells, nicotine acting on α9-containing receptors stimulates the Akt and ERK cell signal transduction pathways, and the use of the α9-selective peptidic antagonist RgIA4 prevents nicotine-induced ERK and Akt phosphorylation. The involvement of α9-containing nAChRs in nicotine-induced proliferation and intracellular signaling in A549 cells has been further confirmed by the fact that silencing experiments using siRNA directed against α9 mRNA replicated the results obtained using RgIA4. All the effects of nicotine on A549 cell proliferation and signaling activation described above are also blocked by the α7-selective toxin AR and the α7- and α9-unselective antagonists MLA and αBgtx, thus suggesting that both receptors have to be activated in order to reach the cytoplasmic Ca²⁺ concentration that triggers the biological effects. In addition, the fact that the nicotine-induced proliferation and intracellular signaling of A549 cells is blocked by α7 and α9 peptidic antagonists that are not cell permeable indicates that the effects of nicotine are due to the activation of the nAChRs present on the plasma membrane.
breast tissue obtained from patients (see Supplementary Table 1), but their expression is higher in breast cancer cells than in the surrounding normal tissue. Not only did 67.3% of their 276 breast cancer tissue samples express high α9 nAChR levels, this expression was higher in the advanced stage III and IV samples than in the early stage I and II samples, and this occurred more often in smokers than in passive smokers or non-smokers.

**α9-Mediated Effects of Nicotine on Breast Cancer Cells**

In order to explore the potential carcinogenic effects of the α9 subunit expressed in normal human breast epithelial cells, Lee et al. (2010) established the MCF-10A normal human breast cell line with the tetracycline-regulated (Tet-off) over-expression of α9 nAChRs, and found that it became potentially carcinogenic in vitro and in vivo. Chen et al. (2011) found that the same line xenografted in BALB/c- nu/nu mice induced cyclin D3 over-expression after exposure to nicotine, whereas silencing α9 nAChR expression in breast cancer cells reduced in vitro and in vivo cyclin D3 levels, cell proliferation, and tumorigenic potential (Chen et al., 2011).

It has been shown that 10 μM nicotine stimulates nAChRs (particularly α9-containing nAChRs) to induce proliferation in two breast cancer cell lines (MCF-7 and MDA-MB-231), and induces the growth of tumors xenografted into SCID mice (Lee et al., 2010). In addition, prolonged exposure of normal MCF-10A human breast to 10 μM nicotine or 1 μM 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) triggers pre-cancerous transformation, an effect that was potentiated by increasing the expression of α9 nAChRs (Lee et al., 2010, 2011). It has also been shown that in MCF-7 human breast cancer cells, nicotine and estrogen induce α9 nAChR expression and that this is transcriptionally regulated by estrogen receptors (ERs). The binding of nicotine to α9-containing nAChRs activates the downstream PI3K, Akt or MAPK signaling pathways, which activates the CHRNA9 promoter region. Nicotine exposure promotes the apoptosis resistance of breast cancer cells by increasing α9 expression, which activates STAT3 nuclear translocation and physical interactions with the promoters of the gene coding for Galectin-3 (LGALS3), an intra-cellular anti-apoptotic α-galactoside-binding lectin (Guha et al., 2014; see Figure 1), and the TWIST1 promoter. Activated STAT3 directly binds these promoters, thus inducing their transcription and up-regulation, and this delays apoptosis and enriches a sub-population of breast cancer cells that have stem cell-like properties.

As it is still debated whether exposure to second-hand smoke (SHS) affects the risk of breast cancer, Fararjeh et al. (2019) used a model of breast cell carcinogenesis in which immortalized normal human breast epithelial cells exposed to a carcinogen undergo long-term exposure to 1 pM nicotine and/or 100 femtM NNK doses (that can be reached during exposure to SHS). They found that repeated co-exposure to nicotine and NNK disrupted cell growth control and led to the acquisition of cancer cell properties, and increased the levels of a number of α9 nAChR downstream signaling proteins, such as the FAK migration marker and the PI3K/Akt intracellular signaling pathway. They also found the increased expression of XIAP (a protein that may play an important role in breast cancer pathogenesis by inhibiting apoptosis) and a decrease in the expression of the pro-apoptotic protein BAX.

Cell invasion and the spread of metastases are crucial processes in tumor development that are regulated by numerous factors, including growth factors, phosphatases, kinases, and extracellular matrix components. PPM1F is a Ser/Thr protein phosphatase that is overexpressed during breast tumor invasion: the levels of PPM1F protein are higher in invasive MDA-MB-231 breast cancer cells than in non-invasive MCF-7 cells, and PPM1F levels are higher in the breast tumor tissue of smokers than in that of non-smokers. Nicotine induces in vitro PPM1F expression, whereas silencing α9 nAChRs reduces PPM1F protein levels, thus ultimately reducing cell motility and invasiveness. Tu et al. (2016) have found that the overexpression of PPM1F reduces the level of phosphorylated p53 and phosphorylated BAX in nicotine-treated MDA-MB-231 cells. These findings show that PPM1F is a phosphatase that inactivates pro-apoptotic proteins (such as BAX) and proteins involved in cell cycle arrest (such as p53), and may be a downstream mediator of α9 nAChRs.

It has recently been shown that breast cancer cell proliferation in vitro can be inhibited by selectively antagonising α9α10 nAChRs (Sun et al., 2020) using the selective aO-conotoxin GeXIVA.

**α9 nAChRs in Triple-Negative Breast Cancer**

Breast cancer negative for ERs, progesterone receptors, and excess human epidermal growth factor receptor 2 protein (triple-negative breast cancer, TNBC) is responsible for 15–20% of all breast cancer cases (Lee et al., 2019).

The over-expression of α9 nAChRs is associated with the poor 5-year disease-specific survival of patients diagnosed as having breast cancer as it up-regulates ER expression. Huang et al. (2017) used a serial spontaneous pulmonary metastasis animal model to generate highly metastatic TNBC cells derived from metastasized lung cells, and found that there was a significant induction of CHRNA9 gene expression and that the level of α9 nAChR expression correlated with the metastatic ability of the tumor. These findings suggest that α9 nAChR expression is required to mediate TNBC metastasis during the development of cancer, and may be a biomarker for targeted therapy.

**α9-Containing Receptors in Gliomas and Glioblastomas**

Gliomas represent 81% of all primary malignant brain tumors in adults, and are one of the most aggressive human cancers (Jemal et al., 2011). The World Health Organisation (WHO) stratifies gliomas into grades I-IV, the most aggressive of which are grade IV astrocytomas or glioblastomas (GBMs; Louis et al., 2001). The World Health Organisation (WHO) stratifies gliomas into grades I-IV, the most aggressive of which are grade IV astrocytomas or glioblastomas (GBMs; Louis et al., 2001). The global incidence of GBMs is 2–5 per 100,000 people and has increased over the last decade (Dobes et al., 2011). Median patient survival is approximately 14–17 months (Zhu et al., 2017), and
the 5-year survival rate is only 5.1% (Ostrom et al., 2015). GBMs originate in brain neural cells and are highly proliferative and invasive. They may begin in astrocytes, glial precursor cells or neural stem cells, but the pathophysiological and molecular mechanisms underlying their malignant transformation are still unclear. The poor prognosis of GBM is primarily attributable to therapeutic resistance and tumor recurrence after surgical removal, which is due to the presence of a small sub-population of self-renewing and proliferative glioblastoma stem cells (GSCs) similar to the neural stem cells from which they may arise.

The results of numerous retrospective studies have failed to show any causal relationship between smoking and gliomas, which is why the hypothesis of a causative link between smoking and the etiology of malignant gliomas remains controversial (Hou et al., 2016; Li et al., 2016).

Very few articles have described studies of the mechanisms of action of nicotine on glioma or GBM cells and, given the limited amount of material available, this review will thoroughly discuss all of the most recent findings.

Khalil et al. (2013) have shown that nicotine concentrations comparable to those found in the serum of chronic smokers enhance GBM cell migration, proliferation, survival, clonogenicity, and radio-resistance partially by activating EGFRs, β-adrenergic receptors, and the Akt and ERK signaling pathways, and that these effects can be blocked by pharmacological inhibitors of the same pathways. Nicotine also promotes tumor growth in nude mice xenografted with human malignant glioma cells, thus suggesting that nicotine exposure may enhance the growth of malignant glioma tumors in vivo.

Spina et al. (2016) correlated glioma patient survival with CHRNA gene expression using the Rembrandt portal, and found that the survival of patients with gliomas or GBMs

1https://caintegrator.nci.nih.gov/rembrandt/
over-expressing CHRNA1 or CHRNA9 is significantly shorter. They used glial fibrillary acidic protein (GFAP) as a reporter of astrocyte differentiation and isolated multiple clones from three independent GSC lines that over-express CHRNA1 or CHRNA9 and express GFAP. Their results showed that high GFAP expression is associated with reduced clonogenicity in vitro and tumorigenicity in vivo. Their screening of chemical libraries revealed that the neuromuscular AChR blocker atracurium besylate inhibits the clonogenic capacity of patient-derived GSCs and induces astroglial differentiation, whereas a nicotinic receptor agonist prevents atracurium besylate from reducing the self-renewal of GSCs. This study also showed a significant improvement in the survival of mice xenotransplanted with GSCs that were pre-treated with atracurium besylate. Taken together, these findings suggest that α1- and α9-containing nAChRs may be intimately involved in controlling GSC fate by reducing their stemness and/or their population.

Thompson and Sontheimer (2019) have very recently investigated the expression of nAChRs and muscarinic receptors (mAChRs) in GBM datasets and cell lines, and patient-derived xenograft lines. Using the RNA-Seq data relating to the tumor samples taken from 156 GBM patients, they analyzed AChR mRNA expression and found that the expression of the large majority of subunits was low, whereas that of the muscle-type α1 and β1 subunits, and the neuronal α9 subunit was high. They used the calcium time-lapse technique to show that the activation of mAChRs or nAChRs increases intracellular Ca\(^{2+}\) in GBM cells. They also showed that there is a nicotine-mediated increase in intracellular Ca\(^{2+}\) that is due to α7 receptors (and probably α9-containing receptors, which are highly permeable to Ca\(^{2+}\) and show increased mRNA expression in patient-derived xenograft GBM lines). In neurons, the time-course of nicotine and ACh activation of the homomeric α7 receptor is very fast (in the order of milliseconds; Papke and Lindstrom, 2020; Borroni and Barrantes, 2021), whereas in GBM cells nicotine activates Ca\(^{2+}\) influx with a time-course of hundreds of seconds. This Ca\(^{2+}\) signaling response persists longer than channel activation and may be the result of CICR from intra-cellular stores, as has been previously shown in the case of hippocampal astrocytes (Sharma and Vijayaraghavan, 2001). It was also demonstrated that the increase in intracellular Ca\(^{2+}\) induced by ACh has minimal effects on cell proliferation or migration, whereas the stimulation of both mAChRs and nAChRs increases GBM cell invasion due to the increased activity of metalloproteinase-9. Our group has also been interested in characterizing the nAChRs in glioblastoma cells. We began by examining publicly available data (accession number GSE16805) from a large-scale, multi-dimensional DNA microarray analysis carried out at IRCSS AOU San Martino-IST (Genoa, Italy), which showed that the most frequently expressed nAChR subunit mRNAs were CHRNA5 and CHRNA9 and, to a lesser extent, CHRNA7 and CHRNA10. We then analyzed the in vitro presence and possible role of nAChRs in U87MG human WHO grade IV astrocytoma U87MG cells and the GBM5 cell line derived from CSC-enriched cultures resistant to temozolomide (TMZ) treatment (Banelli et al., 2015), and found that the expression of nicotinic subunits was similar to that recorded in public databases of GBM patients: highly expressed α9 and α5 subunit mRNAs and less expressed α7 and α10 subunit mRNAs.

The results of our study extended the findings of Khalil et al. (2013) as we found that chronic treatment with nM concentrations of choline or nicotine increases the proliferation of U87MG and GBM5 cells, and activates the anti-apoptotic Akt and pro-proliferative ERK pathways. In general, these effects were blocked by silencing the expression of the α7 and α9 subunits by means of siRNAs or by the non-cell-permeable peptide antagonists selective for α7- and α9-containing nAChRs, thus indicating that they required the presence of both subunits. However, the effects of α7 and α9 were not identical as the action of choline on U87MG and GBM5 cell signaling was not significantly reduced after silencing the α7 subunit, whereas nicotine-induced signaling and choline- and nicotine-stimulated cell proliferation were significantly prevented in both cell lines after silencing either of the subunits. This last finding led us to deduce that choline may act mainly through α9-containing nAChRs, at least in activating GBM5 cell signaling. The α9-containing nAChRs are also involved in basal GBM cell proliferation as it decreased after 6 days of treatment with a subtype-specific agonist (Pucci et al., 2021).

The agonist concentrations that increased cell proliferation were much lower than those necessary to activate α7 (nicotine and choline) or α9 nAChRs (choline) in electrophysiological experiments (Elgoyhen et al., 1994; Corradi and Bouzat, 2016). As nicotine is an antagonist of the ionotropic effects of α9 receptors, the occupation of nAChRs in U87MG and GBM5 cells by low concentration of nicotine leads to a conformational change that may alter interactions between nAChR scaffolds and other intracellular signaling molecules or cytoskeletal elements. This may elicit the non-ionic, metabotropic signaling events that regulate the phosphorylation status of target proteins and thus mediates some of the effects of choline and nicotine.

In our experiments, blocking α7 and/or α9 nAChRs by means of the use of selective antagonists or siRNAs substantially abolished choline- and nicotine-induced cell proliferation and decreased the effects of phosphorylation, which again indicates that the presence of receptors containing both subunits is necessary to ensure the effects of nicotinic agonists. This may be because: (1) it is necessary to have both α7- and α9-containing nAChRs in order to ensure sufficient target cell activation; or (2) GBM cells express heteropentameric α7α9-containing nAChRs which are mainly responsible for the effects of nicotine and choline. Given the difference in the levels of α7 and α9 mRNAs (Pucci et al., 2021), the hypothesis of an α7α9-NaChR subtype may seem to be unlikely at first glance, but it cannot be excluded because the turnover of the two mRNAs may be different, and mRNA levels are not always representative of the expressed protein.

As choline is a precursor of ACh, the increase in GBM cell proliferation may have been due to the direct action of either compounds, but the blocking effect of α7/α9 nicotinic antagonists clearly indicates mediation by nAChRs. Thompson and Sontheimer (2019) found that the expression of the mRNAs of the proteins necessary for ACh synthesis and release (many
choline transporters, choline acetyltransferase, and vesicular acetylcholine transporters) is significantly higher in GBM tissues than in their non-tumoral counterparts, thus suggesting that ACh is the signaling molecule acting on nAChRs.

The α7 and α9α10 nAChRs in GBM cells are pharmacologically similar to those expressed in A549 lung adenocarcinoma cells, whose nicotine-induced activation also increases their proliferation (Mucchietto et al., 2018). This proliferation is blocked in a concentration-dependent manner, by the selective MG624 nicotinic ligand (Gotti et al., 1998). Hybridization of MG624 and a non-nicotinic, resveratrol-derived pro-oxidant mitocan (Bavo et al., 2018) has led to the development of two novel compounds (StN-4 and StN-8) that are more potent than MG624 in reducing the viability of GBM cells, but less potent in reducing the viability of mouse astrocytes (Bavo et al., 2018). Knocking down the α9 subunit in U87MG cells decreases the potency of the effects of both compounds on cell viability, thus clearly indicating that α9-containing nAChRs are involved in sustaining GBM cell growth and survival (Pucci et al., 2022).

### α9-Containing Receptors in Melanoma

Melanoma arises from genetic mutations in melanocytes, and is the most aggressive and deadly skin cancer mainly affecting Caucasians. It accounts for less than 5% of all skin cancers diagnosed annually in the United States, but is responsible for more than 75% of skin cancer deaths (Gershenwald and Guy, 2015).

Studies of 2,583 malignant melanoma patients indicate that smoking facilitates the spread of metastases in both men and women (Shaw and Milton, 1981), and a more recent study of a large sample of current smokers has found a close association between smoking and the occurrence of sentinel lymph node metastases (Jones et al., 2017).

Programmed death-ligand 1 (PD-L1) is a type 1 transmembrane protein encoded by the human CD274 gene that is overexpressed in some types of cancer (Salmaninejad et al., 2019), and PD-1 is an inhibitory receptor encoded by the PDCD1 gene that is located on the surface of all T cells (LaFleur et al., 2018). The PD-1 receptors on activated T cells regulates the immune system during various physiological responses, including the responses to cancer and autoimmune diseases (LaFleur et al., 2018): in particular, the PD-L1/PD-1 axis in a tumor microenvironment is hijacked by cancer cells seeking to avoid immune surveillance (Li et al., 2018).

### α9-Mediated Signaling Pathways in Melanoma

Nguyen et al. (2019) used RT-PCR and Western blotting to analyze the expression of nAChRs and found that the expression of α9 nAChR mRNA was higher that of the other nAChR subunits in three melanoma cell lines (A375, A2058, and MDA-MB-435) and a primary melanocyte cell line (HEMn-LP), and that it was higher in melanoma cells than in melanocytes. They also found correlations between α9 mRNA expression and the clinical parameters of melanoma patients, and that high levels of α9 expression are significantly associated with lymph node metastases.

The in vitro over-expression of α9 in MDA-MB-435 and A2058 melanoma cells increased cell proliferation and migration, and this was paralleled by the activation of the Akt and ERK signaling pathways, and up-regulated PD-L1 expression. Furthermore, the suppression of α9 expression significantly inhibited melanoma cell growth and migration, decreased Akt and ERK activation, and reduced PD-L1 expression.

The over-expression of α9 nAChRs in A2058 and MDA-MB 435 cells also induced mesenchymal-like melanoma cells with the loss of cell-cell adhesion junctions, whereas α9 knockdown in A2058 cells led to an increase in the number of cell-cell adhesion junctions and epithelial-like melanoma cells.

A number of recent studies have shown positive correlations between smoking and PD-L1 expression: Wang et al. (2019) have shown that tobacco smoke induces PD-L1 expression in lung epithelial cells, and Nguyen et al. (2019) have found that nicotine induces α9 nAChR activity promoting melanoma cell proliferation in a dose- and time-dependent manner by stimulating the α9-mediated Akt, ERK, and STAT3 signaling pathways. In addition, nicotine-induced α9 nAChR activity up-regulated PD-L1 expression by activating the binding of transcription factor STAT3 to the PD-L1 promoter gene, thus suggesting that the functional activation of α9 nAChR by nicotine may regulate cancer-related immunity.

### CONCLUSIONS AND PERSPECTIVES

The data described in this review clearly indicate that α9-containing nAChRs play an important role in various cancers. They are expressed in cell types other than neurons and can trigger ion fluxes and/or metabolotropic pathways at different time scales. These receptors are highly permeable to Ca2+ and Thompson and Sontheimer (2019) have indirectly shown that α9 activation increases Ca2+ in cancer cells. This suggests that α9 receptors modulate various fundamental processes in signal transduction, which makes them powerful regulators of responses that stimulate a number of cancer processes, including cell proliferation, the spread of metastases, and the inhibition of apoptosis. This has been clearly established by the work of Lin et al. (2019), who used multiple RNA-seq and microarray datasets to show that α9-interacting proteins and signaling pathways are common in various cancers.

Many studies have shown the involvement of α7 nAChRs in tumor-related processes by using the antagonists αBgt and MLA, which are also active on α9 nAChRs. It is therefore possible that the latter are involved in many more tumor processes than initially hypothesized.

Various clinical studies have shown that the expression of α9 subunits correlates with the unfavorable prognosis of cancer patients, and so α9 nAChRs may act as a novel biomarker when assessing risk and evaluating treatment options.

Greater understanding of the physiological role of α9-containing nAChRs in cells and the molecular mechanisms underlying the way in which they regulate the development of...
cancer will advance our knowledge of the biology and treatment of different cancers, and recognising their importance in the various stages of tumor progression may allow the design of effective anti-cancer drugs and therefore provide more and better options for cancer patients.

AUTHOR CONTRIBUTIONS

SP: conceptualization, conducting the research and investigation process, writing—review and editing. MZ: conceptualization, preparation, creation of the published work, writing—review and editing. FC: conceptualization, supervision, and funding acquisition. CG: conceptualization, supervision, statistical analysis, preparation, creation of the published work, writing—review and editing, and funding acquisition. All authors contributed to the article and approved the submitted version.

FUNDING

SP was the recipient of a fellowship from the Fondazione VALLORO (Milan). This work was supported by Fondazione Monzino (Milan) and Fondazione VALLORO (Milan).

SUPPLEMENTARY MATERIALS

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2021.805123/full#supplementary-material.

REFERENCES

Afrashiteh Nour, M., Hajiajaghzarzadeh, K., Kheradmard, F., Asadzadeh, Z., Bolandi, N., and Baradaran, B. (2021). Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: an emerging targeting candidate. Life Sci. 278:119557. doi: 10.1016/j.lfs.2021.119557

Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2009). Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 89, 73–120. doi: 10.1152/physrev.00015.2008

Banelli, B., Carra, E., Barbieri, F., Wurth, R., Parodi, F., Pattarozzi, A., et al. (2015). The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle 14, 3418–3429. doi: 10.1080/15384101.2015.1090063

Baumann, L., Kauschke, V., Vikman, A., Durselen, L., Krasteva-Christ, G., Kampschulte, M., et al. (2019). Deletion of nicotinic acetylcholine receptor alpha9 in mice resulted in altered bone structure. Bone 120, 285–296. doi: 10.1016/j.bone.2018.11.003

Bavo, F., Pucci, S., Fasoli, F., Lammi, C., Moretti, M., Mucchietto, V., et al. (2018). Potent antiglioblastoma agents by hybridizing the onium-alkaloid-stilbene based structures of an alpha7-nAChR, alpha9-nAChR antagonist and of a pro-oxidant mitocan. J. Med. Chem. 61, 10531–10544. doi: 10.1021/acs.jmedchem.8b01052

Boffi, J. C., Marcovich, I., Gill-Thind, J. K., Corrada, J., Collins, T., Lipovsek, M. M., et al. (2017). Differential contribution of subunit interfaces to modulation of alpha9 nicotinic acetylcholine receptor function. Mol. Pharmacol. 91, 250–262. doi: 10.1124/mol.116.107482

Borroni, V., and Barrantes, F. J. (2021). Homeric and heteromeric alpha7 nicotinic acetylcholine receptors in health and some central nervous system diseases. Membranes (Basel) 11:664. doi: 10.3390/membranes11090664

Bychkov, M., Shenkarev, Z., Shulepko, M., Shlepova, O., Kirpichnikov, M., and Lyukmanova, E. (2019). Water-soluble variant of human Lynx1 induces cell cycle arrest and apoptosis in lung cancer cells via modulation of alpha7 nicotinic acetylcholine receptors. PLoS One 14:e0217339. doi: 10.1371/journal.pone.0217339

Chen, J., Cheuk, I. W. Y., Shin, V. Y., and Kwong, A. (2019). Acetylcholine receptors: Key players in cancer development. Surg. Oncol. 31, 46–53. doi: 10.1016/j.suronc.2019.09.003

Chen, C. S., Lee, C. H., Hsieh, C. D., Ho, C. T., Pan, M. H., Huang, C. S., et al. (2011). Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res. Treat. 125, 73–87. doi: 10.1007/s10549-010-0821-3

Chernyavsky, A. I., Arredondo, J., Vetter, D. E., and Grando, S. A. (2007). The role of alpha9 nicotinic acetylcholine receptor in coordinating keratinocyte adhesion and motility at the initiation of epithelialization. Exp. Cell Res. 313, 3542–3555. doi: 10.1016/j.yexcr.2007.07.011

Chikova, A., Bernard, H. U., Shchepotin, I. B., and Grando, S. A. (2012). New associations of the genetic polymorphisms in nicotinic receptor genes with the risk of lung cancer. Life Sci. 91, 1103–1108. doi: 10.1016/j.lfs.2011.12.023

Colomer, C., Olivos-Ore, L. A., Vincent, A., Mcintosh, J. M., Artalejo, A. R., and Guirineau, N. C. (2010). Functional characterization of alpha9-containing cholinergic nicotinic receptors in the rat adrenal medulla: implication in stress-induced functional plasticity. J. Neurosci. 30, 6732–6742. doi: 10.1523/JNEUROSCI.4997-09.2010

Corradi, J., and Bouzat, C. (2016). Understanding the bases of function and modulation of alpha7 nicotinic receptors: implications for drug discovery. Mol. Pharmacol. 90, 288–299. doi: 10.1124/mol.116.104240

Corringer, P. J., Poitvin, F., Prevost, M. S., Sauguet, L., Delarue, M., and Changeux, J. P. (2012). Structure and pharmacology of pantemeric receptor channels: from bacteria to brain. Structure 20, 941–956. doi: 10.1016/j.str.2012.05.003

Couturier, S., Bertrand, D., Matter, J. M., Hernandez, M. C., Bertrand, S., Millar, N., et al. (1990). A neuronal nicotinic acetylcholine receptor subunit (alpha7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron 5, 847–856. doi: 10.1016/0896-6273(90)90344-f

Crespi, A., Colombo, S. F., and Gotti, C. (2018). Proteins and chemical chaperones involved in neuronal nicotinic receptor expression and function: an update. Br. J. Pharmacol. 175, 1869–1879. doi: 10.1111/bph.13777

Davies, A. R., Hardick, D. J., Blagrbaugh, I. S., Potter, B. V., Wolstenholme, A. J., and Wonnacott, S. (1999). Characterisation of the binding of [H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38, 679–690. doi: 10.1016/S0028-3908(98)00221-4

Dobes, M., Khurana, V. G., Shadbolt, B., Jain, S., Smith, S. F., Smee, R., et al. (2011). Increasing incidence of glioblastoma multiforme and meningioma and decreasing incidence of schwannoma (2000–2008): findings of a multicenter australian study. Surg. Neurol. Int. 2:176. doi: 10.4103/2152-7806.90696

Elgoyhen, A. B., Johnson, D. S., Boulter, J., Vetter, D. E., and Heinemann, S. (1994). Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79, 705–715. doi: 10.1016/0021-9258(94)90555-x

Elgoyhen, A. B., and Katz, E. (2012). The efferent medial olivocochlear-hair cell synapse. J. Physiol. Paris 106, 47–56. doi: 10.1016/j.jphysparis.2011.06.001

Elgoyhen, A. B., Vetter, D. E., Katz, E., Rothlin, C. V., Heinemann, S. F., and Boulter, J. (2001). Alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. U S A 98, 3501–3506. doi: 10.1073/pnas.051622799

Ellison, M., Haberlandt, C., Gomez-Casati, M. E., Watkins, M., Elgoyhen, A. B., Mcintosh, J. M., et al. (2006). Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR. Biochemistry 45, 1511–1517. doi: 10.1021/bi0520129
Wang, G. Z., Zhang, L., Zhao, X. C., Gao, S. H., Qu, L. W., Yu, H., et al. (2019). Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol. 154, 1558–1571. doi: 10.1038/bjp.2008.185

Yu, R., Tae, H. S., Tabassum, N., Shi, J., Jiang, T., and Adams, D. J. (2018). Molecular determinants conferring the stoichiometric-dependent activity of alpha-conotoxins at the human alpha9alpha10 nicotinic acetylcholine receptor subtype. J. Med. Chem. 61, 4628–4634. doi: 10.1021/acs.jmedchem.8b00115

Zhang, Q., Ganapathy, S., Avraham, H., Nishioka, T., and Chen, C. (2020). Nicotine exposure potentiates lung tumorigenesis by perturbing cellular surveillance. Br. J. Cancer 122, 904–911. doi: 10.1038/s41416-020-0730-0

Zheng, N., Christensen, S. B., Dowell, C., Purushottam, L., Skalicky, J. J., McIntosh, J. M., et al. (2021). Discovery of methylene thiasetalc-incorporated alpha-RgIA analogues as potent and stable antagonists of the human alpha9alpha10 nicotinic acetylcholine receptor for the treatment of neuropathic pain. J. Med. Chem. 64, 9513–9524. doi: 10.1021/acs.jmedchem.1c00802

Zhu, P., Du, X. L., Lu, G., and Zhu, J. J. (2017). Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget 8, 44015–44031. doi: 10.18632/oncotarget.17054

Zoli, M., Moretti, M., Zanardi, A., McIntosh, J. M., Clementi, F., and Gotti, C. (2002). Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22, 8785–8789. doi: 10.1523/JNEUROSCI.22-20-08785.2002

Zoli, M., Pistillo, F., and Gotti, C. (2015). Diversity of native nicotinic receptor subtypes in mammalian brain. Neuropharmacology 96, 302–311. doi: 10.1016/j.neuropharm.2014.11.003

Zoli, M., Pucci, S., Vilella, A., and Gotti, C. (2018). Neuronal and extraneuronal nicotinic acetylcholine receptors. Curr. Neuropharmacol. 16, 338–349. doi: 10.2174/1570159X15666170912110450

Zouridakis, M., Giastas, P., Zarkadas, E., Chroni-Tzartou, D., Bregestovski, P., and Tzartos, S. J. (2014). Crystal structures of free and antagonist-bound states of human alpha9 nicotinic receptor extracellular domain. Nat. Struct. Mol. Biol. 21, 976–980. doi: 10.1038/nsmb.2900

Zouridakis, M., Papakyriakou, A., Ivanov, I. A., Kashcheevor, I. E., Tsetlin, V., Tzartos, S., et al. (2019). Crystal structure of the monomeric extracellular domain of alpha9 nicotinic receptor subunit in complex with alpha-conotoxin RgIA: molecular dynamics insights into RgIA binding to alpha9alpha10 nicotinic receptors. Front. Pharmacol. 10:474. doi: 10.3389/fphar.2019.00474

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pucci, Zoli, Clementi and Gotti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, reproduction or republication in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.